LGALS3 and cardiovascular disorder: Its modulation of Gal3, ERK, and Nrf2 pathways aligns with prior evidence and underscores its promise as a multi-targeted therapeutic candidate in cardiovascular disease, providing a basis for mitochondrial quality–associated cardioprotection.